Published on in Vol 23, No 10 (2021): October

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/26890, first published .
ClinicalTrials.gov as a Source of Information About Expanded Access Programs: Cohort Study

ClinicalTrials.gov as a Source of Information About Expanded Access Programs: Cohort Study

ClinicalTrials.gov as a Source of Information About Expanded Access Programs: Cohort Study

Authors of this article:

Jan Borysowski1, 2 Author Orcid Image ;   Andrzej Górski3 Author Orcid Image

Journals

  1. Maeda H, Uchida M, Kusano M, Tsukamoto K, Yamanoi M. Characteristics of the Compassionate Use Program in Japan: An Analysis of Expanded Access Clinical Trials from 2016 to 2021. Clinical Pharmacology & Therapeutics 2022;112(4):817 View
  2. Vermeulen S, Polak T, Bunnik E. Expanded access to investigational drugs in psychiatry: A systematic review. Psychiatry Research 2023;329:115554 View
  3. Miranda A, Rubovits E, Mudar R, Leung V, Raj M. Where are caregivers in the clinical trial? Evaluation of caregiver responsibilities in Alzheimer's disease and related dementias clinical trials. Alzheimer's & Dementia 2023;19(11):5316 View
  4. Bloom T, Bonini K, Gutierrez‐Kapheim M, Kinsley L, Smith M, Duquette D. Exploring genetic counselors' practice of discussing clinical trials with patients. Journal of Genetic Counseling 2024 View